Cantor Fitzgerald Begins Coverage on Voyager Therapeutics (NASDAQ:VYGR)

Research analysts at Cantor Fitzgerald started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Friday, MarketBeat reports. The brokerage set an “overweight” rating and a $5.73 price target on the stock. Cantor Fitzgerald’s target price points to a potential upside of 5.14% from the company’s previous close.

Several other research firms have also weighed in on VYGR. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup began coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. Wedbush initiated coverage on Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $5.45 on Friday. The business has a fifty day moving average of $6.09 and a 200-day moving average of $6.81. Voyager Therapeutics has a twelve month low of $5.19 and a twelve month high of $10.66. The firm has a market cap of $297.71 million, a PE ratio of 7.68 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same period in the prior year, the firm earned ($0.59) earnings per share. On average, analysts anticipate that Voyager Therapeutics will post -0.89 EPS for the current fiscal year.

Insider Activity

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.53% of the stock is owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

A number of large investors have recently bought and sold shares of VYGR. Barclays PLC boosted its stake in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after buying an additional 37,398 shares in the last quarter. Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after purchasing an additional 6,740 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Voyager Therapeutics in the third quarter valued at approximately $6,192,000. Verition Fund Management LLC bought a new stake in shares of Voyager Therapeutics during the third quarter worth $216,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Voyager Therapeutics by 30.5% during the third quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock worth $288,000 after buying an additional 11,516 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.